News Headlines Article

Early-stage Genentech cancer drug combo shows promise
San Francisco Business Times

A combination of two cancer-fighting drugs that block two common cancer pathways is showing promise in an early-stage study, according to Genentech Inc. The South San Francisco-based U.S. arm of Swiss drug maker Roche said at the American Association for Cancer Research conference in Orlando, Fla., this weekend that a combination of the experimental drugs GDC-0973 and GDC-0941 is being tested in a 27-patient study.